文献速递白血病

靶向HDAC3——AKT的新伴侣蛋白,通过DNA损伤应答逆转急性髓系白血病的化疗耐药

Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
PubMed 文献 · Leukemia · 2017-05-02

该研究在急性髓系白血病细胞中发现,化疗药物可上调HDAC3表达,HDAC3通过与AKT结合并在Lys20位点去乙酰化AKT而促进AKT磷酸化,从而介导化疗耐药;HDAC3缺失或抑制可恢复白血病细胞对化疗所致凋亡的敏感性,并在体内减轻MLL-AF9+白血病进展、增强化疗疗效。

要点

  • 化疗药物在诱导DNA损伤的同时上调白血病细胞HDAC3表达。
  • HDAC3结合AKT并在Lys20位点去乙酰化AKT,促进AKT磷酸化。
  • HDAC3抑制在体内减轻MLL-AF9+白血病进展并增敏化疗。

核心结论

  • HDAC3通过调控AKT活化介导急性髓系白血病对化疗药物的耐药。
  • HDAC3缺失或抑制可恢复白血病细胞对化疗所致凋亡的敏感性。
  • 作者认为HDAC3抑制剂与基因毒性药物联合可能成为克服化疗耐药的成功策略。

研究设计与样本

  • 研究在白血病细胞中采用遗传学和药理学方法探讨HDAC3对DNA损伤修复及化疗耐药的作用。
  • 研究在体内采用MLL-AF9+白血病模型评估HDAC3抑制对白血病进展及化疗敏感性的影响。

主要发现

  • 化疗药物在诱导DNA损伤的同时触发白血病细胞HDAC3表达上调。
  • HDAC3与AKT结合并在Lys20位点去乙酰化AKT,促进AKT磷酸化。
  • 化疗药物暴露增强HDAC3与AKT的相互作用,导致AKT乙酰化降低、AKT磷酸化升高。
  • HDAC3缺失或抑制可消除上述反应,同时使白血病细胞对化疗毒性所致凋亡敏感。
  • 体内抑制HDAC3可减轻白血病进展并使MLL-AF9+白血病对化疗敏感。

临床怎么用

  • 作者认为HDAC3抑制剂与基因毒性药物联合可能构成克服化疗耐药的成功策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Resistance to cytotoxic chemotherapy drugs remains as the major cause of treatment failure in acute myeloid leukemia. Histone deacetylases (HDAC) are important regulators to maintain chromatin structure and control DNA damage; nevertheless, how each HDAC regulates genome stability remains unclear, especially under genome stress conditions. Here, we identified a mechanism by which HDAC3 regulates DNA damage repair and mediates resistance to chemotherapy drugs. In addition to inducing DNA damage, chemotherapy drugs trigger upregulation of HDAC3 expression in leukemia cells. Using genetic and pharmacological approaches, we show that HDAC3 contributes to chemotherapy resistance by regulating the activation of AKT, a well-documented factor in drug resistance development. HDAC3 binds to AKT and deacetylates it at the site Lys20, thereby promoting the phosphorylation of AKT. Chemotherapy drug exposure enhances the interaction between HDAC3 and AKT, resulting in decrease in AKT acetylation and increase in AKT phosphorylation. Whereas HDAC3 depletion or inhibition abrogates these responses and meanwhile sensitizes leukemia cells to chemotoxicity-induced apoptosis. Importantly, in vivo HDAC3 suppression reduces leukemia progression and sensitizes MLL-AF9+ leukemia to chemotherapy. Our findings suggest that combination therapy with HDAC3 inhibitor and genotoxic agents may constitute a successful strategy for overcoming chemotherapy resistance.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Long J, Fang WY, Chang L, et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia. 2017. PMID: 28462918. doi:10.1038/leu.2017.130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。